All In Biotech

Drug Trial Radar · NCT00904280

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy of Numorphan® CR (Oxymorphone HCL Controlled Release) in Subjects With Cancer Pain or Chronic Lower Back Pain.

Last checked: Nov 20, 2026Latest source record: May 19, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

239

Actual

Start

Mar 2001

Primary completion

Jul 2003

Study completion Jul 2003

Sponsor

Sponsor type
Industry
First posted
May 19, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and tolerability of oxymorphone ER as an analgesic in cancer and lower back pain subjects having chronic moderate to severe pain.

Conditions

  • Cancers, Pain
  • Lower Back Pain

Interventions

  • Oxymorphone ERDrug

    Open label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monthly assessments of pain with the Brief Pain Inventory (BPI) questionnaire, recall of average pain relief, total rescue medication usage and subject's and physician's global assessment of oxymorphone ERTime frame: 1 year study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Arizona Clinical Research Center

    Tucson, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.